BCAX vs GERN: stock comparison and AI forecast
Bicara Therapeutics Inc. (BCAX) and Geron Corp (GERN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BCAX Bicara Therapeutics Inc.
- Price
- $8.96 -61.3% · 6M
- Market Cap
- $593M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
GERN Geron Corp
- Price
- $0.93 -40.8% · 6M
- Market Cap
- $598M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BCAX and GERN have similar market capitalizations ($593M and $598M).
- Over the last six months GERN returned -40.8% and BCAX -61.3%.
- GERN carries 1.53 times debt per unit of equity, against 0.09 times for BCAX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BCAX | GERN |
|---|---|---|
| Market Cap | $593M | $598M |
| P/B Ratio | 1.26x | 2.65x |
| EPS | $-2.84 | $-0.13 |
| Book Value/Share | $7.08 | $0.35 |
| FCF/Share | $-2.04 | – |
Profitability & Margins
| Metric | BCAX | GERN |
|---|---|---|
| ROE | -39.5% | -45.6% |
| ROA | -36.2% | – |
| ROIC | -43.1% | – |
| Operating Margin | – | -26.5% |
| Net Margin | – | -52.5% |
| EBT Margin | – | -34.0% |
| Tax Rate | -0.1% | – |
Financial Health
| Metric | BCAX | GERN |
|---|---|---|
| Current Ratio | 11.59x | 6.92x |
| Quick Ratio | – | 5.16x |
| D/E Ratio | 0.09x | 1.53x |
| Financial Leverage | 1.09x | – |
| Interest Coverage | – | -2.2x |
| Working Capital | $460M | $416M |
Cash Flow
| Metric | BCAX | GERN |
|---|---|---|
| Operating Cash Flow | -$135M | -$114M |
| Free Cash Flow | -$135M | – |
| Capital Spending | -$400K | – |
Income Statement
| Metric | BCAX | GERN |
|---|---|---|
| Operating Income | -$202M | -$52M |
| Net Income | -$185M | -$103M |
| R&D Expense | $140M | $72M |
| SG&A Expense | – | $155M |
Dividend & Shareholder Information
| Metric | BCAX | GERN |
|---|---|---|
| Shares Outstanding | 66M | 642M |
BCAX vs GERN: stock comparison and AI forecast
Which is bigger, BCAX or GERN?
BCAX and GERN have similar market capitalizations ($593M and $598M).
Which stock performed better over the last six months, BCAX or GERN?
Over the last six months GERN returned -40.8% and BCAX -61.3%.
Which one does Intratio's AI model rank higher, BCAX or GERN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.